1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Neuroimmunology Drugs Market, By Product Type
5.1 Introduction
5.2 Monoclonal Antibodies
5.3 Small Molecules
5.4 Recombinant Protein
5.5 Cytokines
5.6 Lymphocytes
5.7 Other Product Types
6 Global Neuroimmunology Drugs Market, By Indication
6.1 Introduction
6.2 Multiple Sclerosis
6.3 Alzheimer’s Disease
6.4 Parkinson’s Disease
6.5 Myasthenia Gravis
6.6 Guillain-Barre Syndrome
6.7 Neuromyelitis Optica Spectrum Disorder
6.8 Amyotrophic Lateral Sclerosis
6.9 Chronic Inflammatory Demyelinating Polyradiculoneuropathy
6.10 Other Indications
7 Global Neuroimmunology Drugs Market, By Geography
7.1 Introduction
7.2 North America
7.2.1 US
7.2.2 Canada
7.2.3 Mexico
7.3 Europe
7.3.1 Germany
7.3.2 UK
7.3.3 Italy
7.3.4 France
7.3.5 Spain
7.3.6 Rest of Europe
7.4 Asia Pacific
7.4.1 Japan
7.4.2 China
7.4.3 India
7.4.4 Australia
7.4.5 New Zealand
7.4.6 South Korea
7.4.7 Rest of Asia Pacific
7.5 South America
7.5.1 Argentina
7.5.2 Brazil
7.5.3 Chile
7.5.4 Rest of South America
7.6 Middle East & Africa
7.6.1 Saudi Arabia
7.6.2 UAE
7.6.3 Qatar
7.6.4 South Africa
7.6.5 Rest of Middle East & Africa
8 Key Developments
8.1 Agreements, Partnerships, Collaborations and Joint Ventures
8.2 Acquisitions & Mergers
8.3 New Product Launch
8.4 Expansions
8.5 Other Key Strategies
9 Company Profiling
9.1 Biogen
9.2 Hoffmann-La Roche Ltd
9.3 T3D Therapeutics
9.4 Novartis AG
9.5 Celgene Corp
9.6 Merck KGaA
9.7 Johnson & Johnson
9.8 Eisai Co Ltd
9.9 Sanofi
9.10 Actelion Pharmaceuticals Ltd.
9.11 ImmunoBrain Checkpoint
9.12 Lundbeck
9.13 Eli Lilly
9.14 AstraZeneca
9.15 UCB SA
9.16 AB Science S.A.
9.17 AstronauTx
9.18 Genetech Inc
9.19 Inflammasome Therapeutics
9.20 TauRX Therapeutics Ltd
List of Tables
Table 1 Global Neuroimmunology Drugs Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
Table 3 Global Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
Table 4 Global Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
Table 5 Global Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
Table 6 Global Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
Table 7 Global Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
Table 8 Global Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
Table 9 Global Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
Table 10 Global Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
Table 11 Global Neuroimmunology Drugs Market Outlook, By Alzheimer’s Disease (2021-2030) ($MN)
Table 12 Global Neuroimmunology Drugs Market Outlook, By Parkinson’s Disease (2021-2030) ($MN)
Table 13 Global Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
Table 14 Global Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
Table 15 Global Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
Table 16 Global Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
Table 17 Global Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
Table 18 Global Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
Table 19 North America Neuroimmunology Drugs Market Outlook, By Country (2021-2030) ($MN)
Table 20 North America Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
Table 21 North America Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
Table 22 North America Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
Table 23 North America Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
Table 24 North America Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
Table 25 North America Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
Table 26 North America Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
Table 27 North America Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
Table 28 North America Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
Table 29 North America Neuroimmunology Drugs Market Outlook, By Alzheimer’s Disease (2021-2030) ($MN)
Table 30 North America Neuroimmunology Drugs Market Outlook, By Parkinson’s Disease (2021-2030) ($MN)
Table 31 North America Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
Table 32 North America Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
Table 33 North America Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
Table 34 North America Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
Table 35 North America Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
Table 36 North America Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
Table 37 Europe Neuroimmunology Drugs Market Outlook, By Country (2021-2030) ($MN)
Table 38 Europe Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
Table 39 Europe Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
Table 40 Europe Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
Table 41 Europe Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
Table 42 Europe Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
Table 43 Europe Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
Table 44 Europe Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
Table 45 Europe Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
Table 46 Europe Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
Table 47 Europe Neuroimmunology Drugs Market Outlook, By Alzheimer’s Disease (2021-2030) ($MN)
Table 48 Europe Neuroimmunology Drugs Market Outlook, By Parkinson’s Disease (2021-2030) ($MN)
Table 49 Europe Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
Table 50 Europe Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
Table 51 Europe Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
Table 52 Europe Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
Table 53 Europe Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
Table 54 Europe Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
Table 55 Asia Pacific Neuroimmunology Drugs Market Outlook, By Country (2021-2030) ($MN)
Table 56 Asia Pacific Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
Table 57 Asia Pacific Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
Table 58 Asia Pacific Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
Table 59 Asia Pacific Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
Table 60 Asia Pacific Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
Table 61 Asia Pacific Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
Table 62 Asia Pacific Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
Table 63 Asia Pacific Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
Table 64 Asia Pacific Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
Table 65 Asia Pacific Neuroimmunology Drugs Market Outlook, By Alzheimer’s Disease (2021-2030) ($MN)
Table 66 Asia Pacific Neuroimmunology Drugs Market Outlook, By Parkinson’s Disease (2021-2030) ($MN)
Table 67 Asia Pacific Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
Table 68 Asia Pacific Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
Table 69 Asia Pacific Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
Table 70 Asia Pacific Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
Table 71 Asia Pacific Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
Table 72 Asia Pacific Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
Table 73 South America Neuroimmunology Drugs Market Outlook, By Country (2021-2030) ($MN)
Table 74 South America Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
Table 75 South America Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
Table 76 South America Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
Table 77 South America Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
Table 78 South America Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
Table 79 South America Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
Table 80 South America Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
Table 81 South America Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
Table 82 South America Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
Table 83 South America Neuroimmunology Drugs Market Outlook, By Alzheimer’s Disease (2021-2030) ($MN)
Table 84 South America Neuroimmunology Drugs Market Outlook, By Parkinson’s Disease (2021-2030) ($MN)
Table 85 South America Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
Table 86 South America Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
Table 87 South America Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
Table 88 South America Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
Table 89 South America Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
Table 90 South America Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
Table 91 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Country (2021-2030) ($MN)
Table 92 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
Table 93 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
Table 94 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
Table 95 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
Table 96 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
Table 97 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
Table 98 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
Table 99 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
Table 100 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
Table 101 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Alzheimer’s Disease (2021-2030) ($MN)
Table 102 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Parkinson’s Disease (2021-2030) ($MN)
Table 103 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
Table 104 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
Table 105 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
Table 106 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
Table 107 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
Table 108 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
